Pemigatinib is a prescription medication used to treat certain types of locally advanced or metastatic cholangiocarcinoma (cancer of the bile ducts) caused by a genetic mutation called FGFR2 fusions or rearrangements. It is a kinase inhibitor, which works by blocking certain proteins in the body that promote the growth and spread of cancer cells. Pemigatinib is taken as a pill once daily, with or without food. Common side effects may include nausea, fatigue, and joint pain.
Pemigatinib is a medication used to treat a specific type of cancer called cholangiocarcinoma. Here's a closer look at its key features:
What it treats:
- Pemigatinib targets fibroblast growth factor receptor 2 (FGFR2) -positive cholangiocarcinoma. Cholangiocarcinoma is a cancer that forms in the bile ducts, located within the liver and pancreas. Not all cholangiocarcinomas have the FGFR2 mutation, so testing is required to determine if pemigatinib is the appropriate treatment.
How it Works:
- Pemigatinib belongs to a class of drugs called tyrosine kinase inhibitors (TKIs). These medications target specific proteins involved in the growth and spread of cancer cells. In this case, pemigatinib targets the FGFR2 protein. By inhibiting FGFR2, pemigatinib disrupts the signaling pathway that promotes cancer cell growth and survival. This can lead to tumor shrinkage or slower cancer progression.
Important Considerations:
- Dosage and Administration: Pemigatinib is typically given as an oral capsule, taken once daily with or without food. The exact dosage is determined by your doctor based on your individual factors and may be adjusted during treatment.
- Side Effects: Pemigatinib can cause side effects, some common and others more serious. Common side effects include:
- Fatigue
- Dry mouth
- Constipation
- Diarrhea
- Nausea
- Hair loss
- Skin rash
- Joint pain
- Taste changes
Serious side effects may include:
* Interstitial lung disease (inflammation of the lungs)
* Eye problems (dryness, irritation, blurred vision)
* Liver problems
- Monitoring: During pemigatinib treatment, regular monitoring with blood tests and imaging scans is essential to assess treatment response and identify potential side effects.
Additional Notes:
- Pemigatinib is a prescription medication and should only be taken under a doctor's supervision.
- It's vital to discuss the risks and benefits of pemigatinib with your doctor to determine if it's the right treatment for your specific type and stage of cholangiocarcinoma and to understand the potential side effects.
- Pemigatinib is a relatively new medication, and long-term effects are still being studied.